REG - Oxford Biomedica PLC - Director Dealings / Market Share Purchase

Oxford BioMedicaAnnouncement

18/01/2019 10:55

RNS Number : 5243N
Oxford Biomedica PLC
18 January 2019
 


 
 
 
 
 
 
Director Dealings / Market Share Purchase
 
Oxford, UK - 18 January 2019: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Andrew Heath, Deputy Chairman and Senior Independent Director of the Group, has purchased 4,000 ordinary shares of 50p each ("Ordinary Shares") in the Company on 17 January 2019 on the London Stock Exchange at a price of 615.5p. Following this purchase Dr. Andrew Heath holds 40,000 shares representing 0.06% of the Company.
 
2,000 Ordinary Shares were purchased by Dr. Heath's wife (Eva Lackner) and are therefore considered a beneficial holding of Dr. Heath. The balance was purchased in his own name.
 
Stuart Paynter, Chief Financial Officer of the Group, has purchased 1,622 ordinary shares of 50p each ("Ordinary Shares") in the Company on 18 January 2019 on the London Stock Exchange at a price of 612.8p. Following this purchase Stuart Paynter holds 3,375 shares representing 0.005% of the Company.
 
 
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
 
 



 1.


Details of the person discharging material responsibilities/person closely                 associated
 




 a.


Name


 Dr. Andrew Heath
 




 2.


Reason for the notification
 




 a.


Position/status


 Deputy Chairman and Senior Independent Director
 




 b.


Initial notification /amendment


 Initial notification
 




3.


Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
 




 a.


Name


 Oxford BioMedica plc
 




 b.


Legal Entity Identifier


 213800S1GVQNXQ15K851
 




4.


Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




 a.


Description of the financial instrument, type of instrument identification code


 Oxford BioMedica plc Ordinary Shares of 50p each
 
 
 GB00BDFBVT43
 




b.


Nature of the transaction


 Purchase of ordinary shares
 




c.


Currency


 GBP - British Pound
 




d.


Price(s) and volume(s)


 
Price(s)
 


 
Volume(s)




 


 


£6.16


2,000




e.


Aggregated information
·      Aggregated volume
·      Price
·      Aggregated total
 


 
 2,000
 
 £6.155038
 £12,310.08
 




f.


Date of the transaction


 2019-01-17
 




g.


Place of the transaction


 London Stock Exchange, Main Market (XLON)
 



 



 1.


Details of the person discharging material responsibilities/person closely                 associated
 




 a.


Name


 Eva Lackner
 




 2.


Reason for the notification
 




 a.


Position/status


 Person closely associated with Dr. Andrew Heath, Deputy Chairman and Senior Independent Director
 




 b.


Initial notification /amendment


 Initial notification
 




3.


Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
 




 a.


Name


 Oxford BioMedica plc
 




 b.


Legal Entity Identifier


 213800S1GVQNXQ15K851
 




4.


Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




 a.


Description of the financial instrument, type of instrument identification code


 Oxford BioMedica plc Ordinary Shares of 50p each
 
 
 GB00BDFBVT43
 




b.


Nature of the transaction


 Purchase of ordinary shares
 




c.


Currency


 GBP - British Pound
 




d.


Price(s) and volume(s)


 
Price(s)
 


 
Volume(s)




£6.16


2,000




e.


Aggregated information
·      Aggregated volume
·      Price
·      Aggregated total
 


 
 2,000
 
 £6.155038
 £12,310.08
 




f.


Date of the transaction


 2019-01-17
 




g.


Place of the transaction


 London Stock Exchange, Main Market (XLON)
 



 
 



 1.


Details of the person discharging material responsibilities/person closely                 associated
 




 a.


Name


 Stuart Paynter
 




 2.


Reason for the notification
 




 a.


Position/status


 Chief Financial Officer
 




 b.


Initial notification /amendment


 Initial notification
 




3.


Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
 




 a.


Name


 Oxford BioMedica plc
 




 b.


Legal Entity Identifier


 213800S1GVQNXQ15K851
 




4.


Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 




 a.


Description of the financial instrument, type of instrument identification code


 Oxford BioMedica plc Ordinary Shares of 50p each
 
 
 GB00BDFBVT43
 




b.


Nature of the transaction


 Purchase of ordinary shares
 




c.


Currency


 GBP - British Pound
 




d.


Price(s) and volume(s)


 
Price(s)
 


 
Volume(s)




 


 


£6.13


1,622




e.


Aggregated information
·      Aggregated volume
·      Price
·      Aggregated total
 


 
 1,622
 
 £6.1277218
 £9,939.16
 




f.


Date of the transaction


 2019-01-18
 




g.


Place of the transaction


 London Stock Exchange, Main Market (XLON)
 



 
The issued share capital of the Group is 66,103,528 ordinary 50p shares.                      
 
-Ends-
 



For further information, please contact:


 




 
Oxford BioMedica plc:
Stuart Paynter, Company Secretary


 
Tel: +44 (0)1865 783 000



 
Notes for editors
 
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 360 people. Further information is available at www.oxb.com
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHSFUFSAFUSELF